- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01483625
Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection
A 12-week, Randomised, Placebo-controlled, Double-blind, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Patients With Newly Diagnosed and/or Maintenance Treatment naïve Chronic Obstructive Pulmonary Disease (COPD) Experiencing an Acute Respiratory Infection (TICARI 1: Tiotropium In COPD Patients With an Acute Respiratory Infection 1)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
Arizona
-
Tucson, Arizona, États-Unis
- 205.479.01017 Boehringer Ingelheim Investigational Site
-
-
California
-
Riverside, California, États-Unis
- 205.479.01036 Boehringer Ingelheim Investigational Site
-
San Diego, California, États-Unis
- 205.479.01024 Boehringer Ingelheim Investigational Site
-
-
Florida
-
DeLand, Florida, États-Unis
- 205.479.01043 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Florida, États-Unis
- 205.479.01040 Boehringer Ingelheim Investigational Site
-
-
Michigan
-
Chelsea, Michigan, États-Unis
- 205.479.01022 Boehringer Ingelheim Investigational Site
-
-
Mississippi
-
Picayune, Mississippi, États-Unis
- 205.479.01041 Boehringer Ingelheim Investigational Site
-
-
Missouri
-
St. Louis, Missouri, États-Unis
- 205.479.01037 Boehringer Ingelheim Investigational Site
-
-
North Carolina
-
Tabor City, North Carolina, États-Unis
- 205.479.01005 Boehringer Ingelheim Investigational Site
-
Wilmington, North Carolina, États-Unis
- 205.479.01008 Boehringer Ingelheim Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, États-Unis
- 205.479.01003 Boehringer Ingelheim Investigational Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis
- 205.479.01002 Boehringer Ingelheim Investigational Site
-
Tipton, Pennsylvania, États-Unis
- 205.479.01044 Boehringer Ingelheim Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, États-Unis
- 205.479.01006 Boehringer Ingelheim Investigational Site
-
Columbia, South Carolina, États-Unis
- 205.479.01001 Boehringer Ingelheim Investigational Site
-
Easley, South Carolina, États-Unis
- 205.479.01007 Boehringer Ingelheim Investigational Site
-
Fort Mill, South Carolina, États-Unis
- 205.479.01026 Boehringer Ingelheim Investigational Site
-
Gaffney, South Carolina, États-Unis
- 205.479.01031 Boehringer Ingelheim Investigational Site
-
Greenville, South Carolina, États-Unis
- 205.479.01012 Boehringer Ingelheim Investigational Site
-
Hodges, South Carolina, États-Unis
- 205.479.01048 Boehringer Ingelheim Investigational Site
-
Spartanburg, South Carolina, États-Unis
- 205.479.01004 Boehringer Ingelheim Investigational Site
-
Union, South Carolina, États-Unis
- 205.479.01019 Boehringer Ingelheim Investigational Site
-
-
South Dakota
-
Rapid City, South Dakota, États-Unis
- 205.479.01039 Boehringer Ingelheim Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, États-Unis
- 205.479.01033 Boehringer Ingelheim Investigational Site
-
-
Texas
-
Killeen, Texas, États-Unis
- 205.479.01028 Boehringer Ingelheim Investigational Site
-
-
Virginia
-
Ettrick, Virginia, États-Unis
- 205.479.01038 Boehringer Ingelheim Investigational Site
-
Norfolk, Virginia, États-Unis
- 205.479.01047 Boehringer Ingelheim Investigational Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion criteria:
- All patients must sign an informed consent consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial and conducting any study procedures.
- Male or female patients 40 years of age or older.
- Ability to independently read and understand English and/or Spanish.
- Any self-reported history of smoking (e.g. = 100 cigarettes (~5 packs) during life-time).
- Acute respiratory symptoms for up to 7 days
- All patients must have a diagnosis of COPD, and must have an airway obstruction with a post-bronchodilator (Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC)) <0.7. The diagnosis of COPD can be made at Visit 1.
- The clinical assessment of the enrolled patient in the judgement of the investigator supports the introduction of COPD maintenance therapy.
- Patients must be able to inhale medication in a competent manner from the HandiHaler® device and from a metered dose inhaler (MDI)
Exclusion criteria:
Therapy with any long-acting bronchodilator, short-acting anticholinergic, inhaled corticosteroid or regular maintenance use (>14 consecutive days) of systemic corticosteroid (the latter for respiratory indications) during the previous 6 months (short course of systemic corticosteroid for up to 14 days for respiratory indications allowed); in case of use of systemic corticosteroid medication for other than respiratory conditions, then exclusion of unstable doses (i.e., less than six weeks on stable dose) or at doses in excess of the equivalent of 10 mg prednisolone-equivalent per day. In addition, daily use of short-acting beta2-agonist for more than a week prior to Visit 0 not allowed.
The following exclusion criteria apply at Visit 1:
- Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence the patient¿s ability to participate in the study.
- A recent history (i.e., six months or less) of myocardial infarction. Patients being stable with a history of cardiac stents prior to six month are permitted.
- Any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the last year.
- Hospitalisation for cardiac failure (New York Heart Association (NYHA) Class III or IV) during the past year.
- Any significant or new ECG findings at V1 as judged by the investigator, including, but not limited to signs of ischemia, arrhythmia, heart failure, or the report of chest pain.
- Known active tuberculosis.
- Current asthma (patient treated for asthma in the last 2 years), cystic fibrosis, clinical diagnosis of bronchiectasis, interstitial lung disease, or pulmonary thromboembolic disease.
- A history of thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion no. 2.
- Malignancy for which the patient has undergone resection, radiation, chemotherapy or biological treatments within the last year or is currently on active radiation therapy, chemotherapy or biological treatment. Patients with treated basal cell carcinoma are allowed.
- At visit 0 or 1, a severe respiratory infection, e.g. pneumonia (as suspected by investigator), any condition or exacerbation requiring ER visit or hospitalization, need for oxygen treatment.
- Known hypersensitivity to anticholinergic drugs, lactose, or any other components of the HandiHaler® or MDI inhalation solution delivery system.
- Treatment with any restricted pulmonary medication
- Requirement of supplemental oxygen therapy for = 24 hours during the previous 6 months.
- Known moderate to severe renal impairment.
- Known narrow angle glaucoma.
- Significant symptomatic prostatic hyperplasia or bladder-neck obstruction. Patients whose symptoms are controlled on treatment may be included.
- Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e., oral contraceptives, intrauterine devices, diaphragm or subdermal implants e.g., Norplant®) for at least three months prior to and for the duration of the trial.
- Significant alcohol or drug abuse within the past 12 months.
- Actively participating in a pulmonary rehabilitation program.
- Previously randomized in this study or currently participating in another interventional study.
- Visual impairment that as judged by the investigator does not allow the patient to independently read and complete the questionnaires and electronic diary (eDiary).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur placebo: Placebo
placebo
|
placebo
|
Expérimental: tiotropium 18mcg
active
|
18mcg
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Trough FEV1 After 12 Weeks on Study Drug
Délai: 12 weeks
|
The primary endpoint was trough forced expiratory volume in 1 second (FEV1) after 12 weeks on study drug.
Trough forced expiratory volume in 1 second (FEV1)was defined as the FEV1 measurement prior to the next dosing of study drug and approximately 24 hours after the last inhalation of study drug.
|
12 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Time to Recovery From Acute Respiratory Symptoms
Délai: 12 weeks
|
Time to recovery was assessed with the EXACT-PRO questionnaire tool. The EXACT-PRO was designed to collect data to quantify frequency, severity, and duration of exacerbations in patients with COPD including the onset of and the recovery from COPD exacerbations. The EXACT-PRO is a 14-item questionnaire. Each attribute or item was assessed on a five- or six-point ordinal scale and summed to yield a total score that was converted to a 0-100 scale, with higher scores indicating a more severe health state or exacerbation. The EXACT-PRO was answered by the patients on a daily basis in the evening. |
12 weeks
|
Trough FVC (in Litres) at 12 Weeks
Délai: 12 weeks
|
The trough Forced Vital Capacity (FVC) was defined as the FVC measurement prior to the next dosing of study drug and approximately 24 hours after the last inhalation of study drug.
|
12 weeks
|
Responder Status at Week 4 Clinic Visit
Délai: 4 weeks
|
Responder status was determined at each clinic visit. The number and percentage of subjects in each of the following 3 classes were presented:
|
4 weeks
|
Responder Status at Week 12 Clinic Visit
Délai: 12 weeks
|
Responder status was determined at each clinic visit. The number and percentage of subjects in each of the following 3 classes were presented:
|
12 weeks
|
Weekly Rescue Medication Use Over the 12 Weeks of Study
Délai: 12 weeks
|
Daily rescue albuterol use was recorded in the diary in response to the following question: How many puffs of rescue medication did you use during the last 24 hours?
The weekly rescue medication use was derived by summing the daily uses over the 12 weeks and dividing this total by 12 weeks.
|
12 weeks
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Infections
- Maladies des voies respiratoires
- Maladies pulmonaires
- Maladies pulmonaires obstructives
- Maladie pulmonaire obstructive chronique
- Infections des voies respiratoires
- Effets physiologiques des médicaments
- Agents neurotransmetteurs
- Mécanismes moléculaires de l'action pharmacologique
- Parasympatholytiques
- Agents autonomes
- Agents du système nerveux périphérique
- Antagonistes cholinergiques
- Agents cholinergiques
- Agents bronchodilatateurs
- Agents anti-asthmatiques
- Agents du système respiratoire
- Bromure de tiotropium
Autres numéros d'identification d'étude
- 205.479
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Placebo
-
SamA Pharmaceutical Co., LtdInconnueBronchite aiguë | Infection aiguë des voies respiratoires supérieuresCorée, République de
-
National Institute on Drug Abuse (NIDA)ComplétéConsommation de cannabisÉtats-Unis
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingComplétéMaladie de ParkinsonChine
-
Heptares Therapeutics LimitedComplétéPharmacocinétique | Des problèmes de sécuritéRoyaume-Uni
-
West Penn Allegheny Health SystemComplétéAsthme | Rhinite allergiqueÉtats-Unis
-
ItalfarmacoComplétéDystrophie musculaire de BeckerPays-Bas, Italie
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyComplétéSujets masculins atteints de diabète de type II (T2DM)Allemagne
-
Longeveron Inc.RésiliéSyndrome hypoplasique du cœur gaucheÉtats-Unis
-
Chong Kun Dang PharmaceuticalInconnueHypertension | DyslipidémiesCorée, République de